Acorda Therapeutics

Acorda Therapeutics, Inc. engages in the development of therapies that restore function and improve the lives of people with neurological disorders. Its products include Inbrija (levodopa inhalation powder), Ampyra (dalfampridine), Fampyra (fampridine) and Selincro (nalmefene). The firm's also offers Research and Development Programs like ARCUS for acute migraine, Cimaglermin alfa and rHIgM22. The company was founded by Ronald Cohen in 1995 and is headquartered in Ardsley, NY.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Global Ecology Corp. engages in the development, production and marketing of advanced waste remediation technologies that address universal environmental issues, which include organic soil revitalization, reduction of greenhouse gas emissions, solid waste remediation and point-of-use water purification solutions. The company was founded in 1993 and is headquartered in Las Vegas, NV.

Acorda's (ACOR) earnings and revenues fall shy of estimates in the first quarter of 2020. The company withdraws revenue view for its Parkinson's disease drug Inbrija due to the ongoing COVID-19 pandemic.

Acorda (ACOR) Q1 Earnings Lag Estimates, Revenues Fall Y/Y

Acorda Therapeutics, Inc. (ACOR) CEO Ron Cohen on Q1 2020 Results - Earnings Call Transcript

Acorda (ACOR) delivered earnings and revenue surprises of -45.71% and -28.58%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Acorda Therapeutics (ACOR) Reports Q1 Loss, Misses Revenue Estimates

During Acorda's (ACOR) upcoming Q1 earnings call, investor focus will be on the sales uptake of its newly-launched Parkinson's disease drug, Inbrija.

Acorda (ACOR) to Report Q1 Earnings: What's in the Cards?

Acorda Therapeutics (ACOR) closed the most recent trading day at $1.06, making no change from the previous trading session.

Acorda Therapeutics (ACOR) Flat As Market Gains: What You Should Know

Acorda Therapeutics (ACOR) closed the most recent trading day at $0.93, moving -0.11% from the previous trading session.

Acorda Therapeutics (ACOR) Stock Moves -0.11%: What You Should Know

Acorda (ACOR) reported earnings 30 days ago. What's next for the stock?

Why Is Acorda (ACOR) Down 54.7% Since Last Earnings Report?

Acorda (ACOR) beat earnings and revenue estimates in the fourth quarter of 2019.

Acorda (ACOR) Q4 Earnings Top Estimates, Revenues Fall Y/Y

Acorda Therapeutics, Inc. (ACOR) CEO Ron Cohen on Q4 2019 Results - Earnings Call Transcript

Acorda (ACOR) reports lower-than-expected loss in the fourth quarter while revenues beat estimates.

Acorda (ACOR) Beats Earnings & Revenues Estimates in Q4

During Acorda's (ACOR) Q4 earnings call, investor focus will be on the sales uptake of its newly-launched Parkinson's disease drug Inbrija.

What's in Store for Acorda (ACOR) This Earnings Season?

Acorda (ACOR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Acorda Therapeutics (ACOR) Q4 Earnings Expected to Decline

Acorda Therapeutics (ACOR) shares rose nearly 6% in the last trading session, amid huge volumes.

Acorda Therapeutics (ACOR) in Focus: Stock Moves 5.7% Higher

Acorda (ACOR) Down 13.5% Since Last Earnings Report: Can It Rebound?

Acorda's (ACOR) lead MS drug Ampyra is hit by generic competition in the United States, which is hurting the company's top line of late. Parkinson's disease drug Inbrija seems an ideal replacement.

Acorda (ACOR) Down More Than 80% Year to Date: Here's Why

Acorda (ACOR) posts narrower-than-expected loss with revenues also topping estimates in the third quarter. Inbrija is also off to a promising start with sales rising sequentially.

Acorda (ACOR) Q3 Earnings and Revenues Surpass Estimates

Acorda Therapeutics, Inc. (ACOR) CEO Ron Cohen on Q3 2019 Results - Earnings Call Transcript

Acorda (ACOR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Acorda Therapeutics (ACOR) Expected to Beat Earnings Estimates: Should You Buy?

During Acorda's (ACOR) third-quarter earnings call, investor focus will be on the sales uptick of its newly launched Parkinson's disease drug Inbrija.

Acorda (ACOR) to Post Q3 Earnings: What's in the Cards?

Acorda (ACOR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Acorda (ACOR) Upgraded to Buy: Here's What You Should Know

Acceleron Pharma's (XLRN) pipeline candidate, ACE-083, fails to translate muscle volume growth into improvements in functional tests in FSHD patients. Acceleron discontinues development.

Acceleron Discontinues Mid-Stage Muscular Dystrophy Study

Acorda's (ACOR) lead MS drug Ampyra is hit by generic rivalry in the United States, which is hurting the company's top line. Parkinson's disease drug Inbrija can be an ideal replacement.

Acorda (ACOR) Down More Than 60% in 3 Months: Here's Why

Why Is Acorda (ACOR) Down 46.8% Since Last Earnings Report?

Acorda Therapeutics has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Acorda Therapeutics Enters Oversold Territory

Acorda recently announced a Q2 earnings beat for both EPS and revenue. However, the market didn't approve of INBRIJA's launch progress. I review the details of the earnings report.

News for Acorda Therapeutics Stock (ACOR)